Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant ...

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

The FDA has accepted for review the NDA for vepdegestrant to treat ESR1-mutated, ER+, HER2- advanced breast cancer.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

Dr Hope Rugo explores how evolving endocrine strategies and targeted therapies are enhancing outcomes in hormone ...

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT ...

Melissa Louise Pilewskie, MD, clinical associate professor in the department of surgery and co-director of the Weiser Family Center for Breast Cancer at Michigan Medicine, discusses treatment options ...

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ...